- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharmaceutical Executive's 2023 Emerging Pharma Leaders
Pharm Exec profiles its 2023 Emerging Pharma Leaders.
2023 Emerging Pharma Leaders
Each year, Pharmaceutical Executive recognizes up-and-coming leaders who are vital to the future of the pharmaceutical and biotech industry in the Emerging Pharma Leaders (EPL) Awards. Nominations are judged by three members of the Editorial Advisory Board as well as a former EPL representative. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with executives most likely to inhabit key “c-suite” functions.
The Pharm Exec team would like to congratulate the 2023 Emerging Pharma Leaders:
- Natasha A. Hernday, chief business officer, Seagen
- Simon Holland, vice president, women's health commercial lead, Organon
- Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio
- Frank Watanabe, president and CEO, Arcutis Biotherapeutics
- Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics
To learn more about this year’s winners, you can also:
Lykos Therapeutics Reshuffles Board of Directors Following FDA Rejection of Midomafetamine Capsules
January 15th 2025During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.
